Business
Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for t...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic Esophagitis\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n No serious or treatment related adverse events in either the first or second cohort\n \n \n Second cohort demonstrated an average 60% reduction in Dysphasia Likert score and an average 80% reduction in Odynophagia Likert score\n \n \n First cohort maintaining signs of efficacy to six months\n \n \n Third cohort now fully dosed at five times the first cohort dose and two-and-a-half times the second cohort dose\n \n \n Results from third cohort are expected in the second quarter of 2024\n \n \n \n \n \n VICTORIA, BC\n \n \n ,\n \n \n Feb. 5, 2024\n \n \n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced updated positive clinical data from its Phase\n \n 1b\n \n /2a RESOLVE trial, which is evaluating safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis (\"EoE\").\n \n \n EoE is a life altering, chronic, immune-mediated condition of the esophagus that causes inflammation, structural damage and dysfunction when left untreated.  Patients with EoE experience difficulty and pain in swallowing; the extent of which can dramatically affect their quality of life.  Current treatment options often provide poor or temporary control over the condition and can be accompanied with unpleasant side effects, such as oral fungal infections.\n \n \n \"Our goal for EP-104GI is to develop a product that provides potent and targeted immunotherapy to the esophagus with minimal systemic exposure and side effects,\" said Dr.\n \n James Helliwell\n \n , CEO of Eupraxia. \"The updated data announced today from our RESOLVE trial in EoE demonstrate good tolerability and early efficacy signals from patients treated wi...